Fascinating.
That explains the apparent duplication.
And it keeps patent lawyers busy.
I guess applicants can't ask to be assigned to their favourite examiner.
Is there a benefit in asking two patent lawyers to patent the same invention in case they express the claims differently?
- Forums
- ASX - By Stock
- RAC
- Ann: Zantrene highly effective in Melanoma preclinical study
Ann: Zantrene highly effective in Melanoma preclinical study, page-178
-
-
- There are more pages in this discussion • 2 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add RAC (ASX) to my watchlist
|
|||||
Last
$1.65 |
Change
-0.015(0.90%) |
Mkt cap ! $276.8M |
Open | High | Low | Value | Volume |
$1.68 | $1.68 | $1.61 | $156.3K | 95.82K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
2 | 4344 | $1.64 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$1.66 | 2731 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 698 | 1.640 |
1 | 12505 | 1.635 |
1 | 7271 | 1.630 |
1 | 31221 | 1.625 |
1 | 2180 | 1.620 |
Price($) | Vol. | No. |
---|---|---|
1.650 | 3612 | 1 |
1.655 | 2153 | 1 |
1.660 | 147 | 1 |
1.675 | 5152 | 1 |
1.680 | 5550 | 2 |
Last trade - 15.49pm 06/09/2024 (20 minute delay) ? |
Featured News
RAC (ASX) Chart |